Namyangju-si, '2024~2025 Seasonal COVID-19 Vaccination Campaign' 실시
"Reduces Risk of Severe Condition"
Namyangju City, Gyeonggi Province (Mayor Joo Gwang-deok) announced on the 22nd that it will conduct the "2024-2025 Seasonal COVID-19 Free Vaccination" from the 11th of this month until April 30th of next year to protect the health of high-risk groups and reduce the risk of severe complications.
This vaccination will be carried out sequentially by age group, starting with seniors aged 75 and older, and will also include immunocompromised individuals and residents or inpatients of infection-vulnerable facilities.
The city will use the JN.1 vaccines (Pfizer, Moderna, Novamax) for this vaccination, and eligible recipients can choose their preferred vaccine at designated medical institutions.
The list of designated medical institutions can be found on the COVID-19 Vaccination Helper website under ‘Vaccination Management → Find Designated Medical Institutions’ or on the Namyangju City Health Center website (health → Medical Examination/Test → COVID-19 Vaccination).
In particular, seniors aged 65 and older can receive the COVID-19 vaccine and the influenza (flu) vaccine simultaneously. The two vaccines are administered at different sites, forming immunity without mutual interference, allowing seniors to prevent both diseases in a single visit.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Jung Tae-sik, Director of Namyangju Health Center, emphasized, “COVID-19 remains a threat, and immunity gained from previous vaccinations and natural infections decreases over time,” adding, “Those in high-risk groups are strongly urged to protect their health by receiving this new vaccination.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.